165 related articles for article (PubMed ID: 14500395)
1. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth.
Strock CJ; Park JI; Rosen M; Dionne C; Ruggeri B; Jones-Bolin S; Denmeade SR; Ball DW; Nelkin BD
Cancer Res; 2003 Sep; 63(17):5559-63. PubMed ID: 14500395
[TBL] [Abstract][Full Text] [Related]
2. RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571.
Skinner MA; Safford SD; Freemerman AJ
Anticancer Res; 2003; 23(5A):3601-6. PubMed ID: 14666655
[TBL] [Abstract][Full Text] [Related]
3. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations.
de Groot JW; Plaza Menacho I; Schepers H; Drenth-Diephuis LJ; Osinga J; Plukker JT; Links TP; Eggen BJ; Hofstra RM
Surgery; 2006 Jun; 139(6):806-14. PubMed ID: 16782438
[TBL] [Abstract][Full Text] [Related]
4. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.
Cuccuru G; Lanzi C; Cassinelli G; Pratesi G; Tortoreto M; Petrangolini G; Seregni E; Martinetti A; Laccabue D; Zanchi C; Zunino F
J Natl Cancer Inst; 2004 Jul; 96(13):1006-14. PubMed ID: 15240784
[TBL] [Abstract][Full Text] [Related]
5. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.
Petrangolini G; Cuccuru G; Lanzi C; Tortoreto M; Belluco S; Pratesi G; Cassinelli G; Zunino F
Biochem Pharmacol; 2006 Aug; 72(4):405-14. PubMed ID: 16756963
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth.
Ezzat S; Huang P; Dackiw A; Asa SL
Clin Cancer Res; 2005 Feb; 11(3):1336-41. PubMed ID: 15709206
[TBL] [Abstract][Full Text] [Related]
7. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.
Johanson V; Ahlman H; Bernhardt P; Jansson S; Kölby L; Persson F; Stenman G; Swärd C; Wängberg B; Stridsberg M; Nilsson O
Endocr Relat Cancer; 2007 Jun; 14(2):433-44. PubMed ID: 17639056
[TBL] [Abstract][Full Text] [Related]
8. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM
Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946
[TBL] [Abstract][Full Text] [Related]
10. Re: "Inhibition of medullary thyroid carcinoma (MTC) cell proliferation and RET phosphorylation by tyrosine kinase inhibitors".
Plaza Menacho I; de Groot JW; Links T; Plukker J; Eggen BJ; Hofstra R
Surgery; 2004 Feb; 135(2):240-1; author reply 241. PubMed ID: 14760839
[No Abstract] [Full Text] [Related]
11. Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer.
Strock CJ; Park JI; Rosen DM; Ruggeri B; Denmeade SR; Ball DW; Nelkin BD
J Clin Endocrinol Metab; 2006 Jan; 91(1):79-84. PubMed ID: 16263812
[TBL] [Abstract][Full Text] [Related]
12. Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model.
Drosten M; Stiewe T; Pützer BM
Hum Gene Ther; 2003 Jul; 14(10):971-82. PubMed ID: 12869215
[TBL] [Abstract][Full Text] [Related]
13. Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells.
Arthan D; Hong SK; Park JI
Cancer Lett; 2010 Nov; 297(1):31-41. PubMed ID: 20570039
[TBL] [Abstract][Full Text] [Related]
14. RET signals through focal adhesion kinase in medullary thyroid cancer cells.
Panta GR; Nwariaku F; Kim LT
Surgery; 2004 Dec; 136(6):1212-7. PubMed ID: 15657578
[TBL] [Abstract][Full Text] [Related]
15. Targeting RET receptor tyrosine kinase activation in cancer.
Phay JE; Shah MH
Clin Cancer Res; 2010 Dec; 16(24):5936-41. PubMed ID: 20930041
[TBL] [Abstract][Full Text] [Related]
16. Interplay between Ret and Fap-1 regulates CD95-mediated apoptosis in medullary thyroid cancer cells.
Nicolini V; Cassinelli G; Cuccuru G; Bongarzone I; Petrangolini G; Tortoreto M; Mondellini P; Casalini P; Favini E; Zaffaroni N; Zunino F; Lanzi C
Biochem Pharmacol; 2011 Oct; 82(7):778-88. PubMed ID: 21741956
[TBL] [Abstract][Full Text] [Related]
17. Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes.
Quayle FJ; Moley JF
J Surg Oncol; 2005 Mar; 89(3):122-9. PubMed ID: 15719378
[TBL] [Abstract][Full Text] [Related]
18. Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.
Gorla L; Mondellini P; Cuccuru G; Miccichè F; Cassinelli G; Cremona M; Pierotti MA; Lanzi C; Bongarzone I
Mol Carcinog; 2009 Mar; 48(3):220-231. PubMed ID: 18756447
[TBL] [Abstract][Full Text] [Related]
19. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan.
Kameyama K; Okinaga H; Takami H
Biomed Pharmacother; 2004; 58(6-7):345-7. PubMed ID: 15271413
[TBL] [Abstract][Full Text] [Related]
20. BAY 43-9006 inhibition of oncogenic RET mutants.
Carlomagno F; Anaganti S; Guida T; Salvatore G; Troncone G; Wilhelm SM; Santoro M
J Natl Cancer Inst; 2006 Mar; 98(5):326-34. PubMed ID: 16507829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]